Related references
Note: Only part of the references are listed.Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer
Ying-Na Li et al.
APMIS (2014)
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
Pernelle Lavaud et al.
BMC MEDICINE (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Johanna Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Serum HER2 levels determined by two methods in patients with metastatic breast cancer
Naoki Hayashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis
Hirotaka Tanaka et al.
SCIENTIFIC REPORTS (2012)
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Identification of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR
Hyun-Wook Rho et al.
BMC CANCER (2010)
Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
April A. N. Rose et al.
CLINICAL CANCER RESEARCH (2010)
New Strategies in Estrogen Receptor-Positive Breast Cancer
Stephen R. D. Johnston
CLINICAL CANCER RESEARCH (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
David Cameron et al.
ONCOLOGIST (2010)
ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties
April A. N. Rose et al.
PLOS ONE (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Evaluation of serum HER2 extracellular domain in early breast cancer patients:: correlation with clinicopathological parameters and survival
V. Ludovini et al.
ANNALS OF ONCOLOGY (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function
Samir M. Abdelmagid et al.
EXPERIMENTAL CELL RESEARCH (2008)
Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate
Xiaozhong Qian et al.
MOLECULAR ONCOLOGY (2008)
Osteoactivin promotes breast cancer metastasis to bone
April A. N. Rose et al.
MOLECULAR CANCER RESEARCH (2007)
Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p2l1.3, in p53-regulated tumor angiogenesis suppression
Manabu Futamura et al.
CANCER RESEARCH (2007)
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme
CT Kuan et al.
CLINICAL CANCER RESEARCH (2006)
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
M Dowsett et al.
ENDOCRINE-RELATED CANCER (2005)
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
WJ Köstler et al.
CLINICAL CANCER RESEARCH (2004)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
MD Pegram et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P
PS Bandari et al.
REGULATORY PEPTIDES (2003)
Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts
FF Safadi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2002)
Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans
S Shikano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
